Beth A. Kurt
Experienced in Non-Langerhans-Cell Histiocytosis

Dr. Beth A. Kurt

Pediatric Hematology Oncology
35 Michigan Street Northeast, Floor 2, 
Grand Rapids, MI 
On Staff At
24 Years of Experience
Experienced in Non-Langerhans-Cell Histiocytosis
35 Michigan Street Northeast, Floor 2, 
Grand Rapids, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Beth Kurt is a Pediatric Hematologist Oncology provider in Grand Rapids, Michigan. Dr. Kurt has been practicing medicine for over 24 years and is rated as an Experienced provider by MediFind in the treatment of Non-Langerhans-Cell Histiocytosis. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hereditary Spherocytosis, Congenital Athymia, and Febrile Neutropenia.

Her clinical research consists of co-authoring 7 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 2 clinical trials in the study of Non-Langerhans-Cell Histiocytosis.

Graduate Institution
Michigan State University College Of Human Medicine, 2001
Residency
Corewell Health/MSU College of Human Medicine
Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MI
Board Certifications
American Board Of Pediatrics
American Board Of Internal Medicine
American Board Of Pediatrics
Fellowships
St. Jude Children's Research Hospital-GME
Hospital Affiliations
Corewell Health Grand Rapids Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
View 8 Less Insurance Carriers -

Locations

Corewell Health Grand Rapids Hospitals Pediatric Cancer Hematology - 35 Michigan St NE
35 Michigan Street Northeast, Floor 2, Grand Rapids, MI 49503
Other Locations
Helen DeVos Pediatric Clinic - Hematology/Oncology
3950 Hollywood Road, Suite 240, Saint Joseph, MI 49085
Corewell Health Grand Rapids Hospitals Pediatric Hematology/Oncology - Traverse City
217 South Madison Street, Traverse City, MI 49684

Additional Areas of Focus

Dr. Kurt has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

7 Total Publications

Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.
Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.
Journal: Haematologica
Published: April 22, 2025
Similar Doctors
Jessica M. Foley
Experienced in Non-Langerhans-Cell Histiocytosis
Dr. Jessica M. Foley
Pediatric Hematology Oncology
Experienced in Non-Langerhans-Cell Histiocytosis
Dr. Jessica M. Foley
Pediatric Hematology Oncology

Corewell Health Grand Rapids Hospitals Pediatric Cancer Hematology - 35 Michigan St NE

35 Michigan Street Northeast, Floor 2, 
Grand Rapids, MI 
 (0.1 miles away)
616-267-1925
Experience:
18+ years
Languages Spoken:
English
See accepted insurances

Jessica Foley is a Pediatric Hematologist Oncology provider in Grand Rapids, Michigan. Dr. Foley has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Non-Langerhans-Cell Histiocytosis. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hereditary Spherocytosis, Hemophilia A, and Hemophilic Arthropathy.

Kristy L. Pilbeam
Experienced in Non-Langerhans-Cell Histiocytosis
Dr. Kristy L. Pilbeam
Pediatric Hematology Oncology
Experienced in Non-Langerhans-Cell Histiocytosis
Dr. Kristy L. Pilbeam
Pediatric Hematology Oncology

Corewell Health Grand Rapids Hospitals Pediatric Cancer Hematology - 35 Michigan St NE

35 Michigan Street Northeast, Floor 2, 
Grand Rapids, MI 
 (0.1 miles away)
616-267-1925
Experience:
14+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kristy Pilbeam is a Pediatric Hematologist Oncology provider in Grand Rapids, Michigan. Dr. Pilbeam has been practicing medicine for over 14 years and is rated as an Advanced provider by MediFind in the treatment of Non-Langerhans-Cell Histiocytosis. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Langerhans Cell Histiocytosis, Ewing Sarcoma, and Neuroblastoma. Dr. Pilbeam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kurt's expertise for a condition
ConditionClose
      View All 55 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile